MOXO Mobile the first Attention Deficit Hyperactive Disorder ADHD screening m...
MOXO Mobile the first Attention Deficit Hyperactive Disorder ADHD screening mobile application using Eye Tracking and Continuous Performance Test components to give the first evidence of attention
Undiagnosed ADHD leads to learning and social difficulties, school drop-out, unemployment, criminality, and even premature death.
Early diagnosis can dramatically improve the quality of life of at least 26 million individuals in...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Undiagnosed ADHD leads to learning and social difficulties, school drop-out, unemployment, criminality, and even premature death.
Early diagnosis can dramatically improve the quality of life of at least 26 million individuals in the EU, prevent incarceration and recidivism, and save lives.
MOXO-Mobile is the first ADHD screening mobile application, combining a Continuous Performance Test (CPT) and Eye Tracking (ET) to give an accurate and simple evaluation of the evidence of attentional difficulties. Using this application, every smartphone user could assess his/her attention level and profile and receive further guidance, in case of need, for further diagnosis.
The application will be downloaded for free with pay-per-use strategy as the user will purchase tests as he wishes for himself and his family.
MOXO-Mobile will create a new market (ADHD screening), with max market potential of €2.8B, and a projected ROI of 6.1 in 3 years for MOXO-Mobile.
SMEi Phase 1 will enable Neurotech-Solutions to conduct a wide feasibility study, establish an elaborated business plan, risk
assessment, and a sustainability estimation of the product.